| For: | Ocker M. Fibroblast growth factor signaling in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Paving the way to hepatocellular carcinoma. World J Gastroenterol 2020; 26(3): 279-290 [PMID: 31988589 DOI: 10.3748/wjg.v26.i3.279] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v26/i3/279.htm |
| Number | Citing Articles |
| 1 |
Zhaoqiang Chen, Zepeng Zhang, Jiaqi Liu, Hongyu Qi, Jing Li, Jinjin Chen, Qingxia Huang, Qing Liu, Jia Mi, Xiangyan Li. Gut Microbiota: Therapeutic Targets of Ginseng Against Multiple Disorders and Ginsenoside Transformation. Frontiers in Cellular and Infection Microbiology 2022; 12 doi: 10.3389/fcimb.2022.853981
|
| 2 |
Zhen Yang, Lin Wang. Current, emerging, and potential therapies for non-alcoholic steatohepatitis. Frontiers in Pharmacology 2023; 14 doi: 10.3389/fphar.2023.1152042
|
| 3 |
Magdelyn Mei-Theng Wong, Hui-Yin Chan, Norazlin Abdul Aziz, Thamil Selvee Ramasamy, Jan-Jin Bong, Ewe Seng Ch’ng, Subasri Armon, Suat-Cheng Peh, Sin-Yeang Teow. Interplay of autophagy and cancer stem cells in hepatocellular carcinoma. Molecular Biology Reports 2021; 48(4) doi: 10.1007/s11033-021-06334-9
|
| 4 |
Peter Ellinghaus, Daniel Neureiter, Hendrik Nogai, Sebastian Stintzing, Matthias Ocker. Patient Selection Approaches in FGFR Inhibitor Trials—Many Paths to the Same End?. Cells 2022; 11(19) doi: 10.3390/cells11193180
|
| 5 |
Venkateswararao Eeda, Nikhil Yuvaraj Patil, Aditya Dilip Joshi, Vibhudutta Awasthi. Advancements in metabolic‐associated steatotic liver disease research: Diagnostics, small molecule developments, and future directions. Hepatology Research 2024; 54(3) doi: 10.1111/hepr.14008
|
| 6 |
Jiejun Yan, Qian Hou, Jing Liu, Weilan Li. Insights Into the Mechanism of Action for Qingzhi Decoction for the Treatment of Non‐Alcoholic Fatty Liver Disease via Regulation of the IRS/PI3K/Akt Signaling Pathway and the NRLP3 Inflammasome. Biomedical Chromatography 2025; 39(9) doi: 10.1002/bmc.70156
|
| 7 |
Olga Pavlova, Natalia Shevchenko, Sergey Pavlov, Tetiana Holovko, Liudmyla Bogmat. Predictors of fibrogenesis in children with JIA: a single-center pilot study. Pediatric Rheumatology 2024; 22(1) doi: 10.1186/s12969-023-00937-1
|
| 8 |
Sachithra S. Ranaweera, Premkumar Natraj, Priyanka Rajan, Laksi A. Dayarathne, Suyama P. Mihindukulasooriya, Duong Thi Thuy Dinh, Youngheun Jee, Chang-Hoon Han. Anti-obesity effect of sulforaphane in broccoli leaf extract on 3T3-L1 adipocytes and ob/ob mice. The Journal of Nutritional Biochemistry 2022; 100 doi: 10.1016/j.jnutbio.2021.108885
|
| 9 |
Chao Yang, Min Wan, Dengfeng Xu, Da Pan, Hui Xia, Ligang Yang, Guiju Sun. Flaxseed Powder Attenuates Non-Alcoholic Steatohepatitis via Modulation of Gut Microbiota and Bile Acid Metabolism through Gut–Liver Axis. International Journal of Molecular Sciences 2021; 22(19) doi: 10.3390/ijms221910858
|
| 10 |
Hancheng Yu, Yumei Huang, Jingyao Wang, Jijuan Zhang, Ling Yang, Tingting Geng, Gang Liu, An Pan, Yunfei Liao. Large‐Scale Plasma Proteomics Improves Prediction of Major Adverse Liver Outcomes in Individuals With MASLD. Diabetes, Obesity and Metabolism 2026; 28(7) doi: 10.1111/dom.70824
|
| 11 |
Shreya C. Pal, Stephany M. Castillo-Castañeda, Luis E. Díaz-Orozco, Mariana M. Ramírez-Mejía, Rita Dorantes-Heredia, Rogelio Alonso-Morales, Mohammed Eslam, Frank Lammert, Nahum Méndez-Sánchez. Molecular Mechanisms Involved in MAFLD in Cholecystectomized Patients: A Cohort Study. Genes 2023; 14(10) doi: 10.3390/genes14101935
|
| 12 |
Wei Wang, Lina Ma, Ying Chen, Rongguang Kuang, Fengyan Wang, Liyun Wang. Effect of circulating exosomal miRNA-122-3p on metabolic dysfunction-associated steatotic liver disease through impairing FGFR4 expression. Chinese Medical Journal 2026; doi: 10.1097/CM9.0000000000004003
|
| 13 |
Pranav Patel. Treatment Landscape of Metabolic-Dysfunction-Associated Steatotic Liver Disease. Journal of Clinical Medicine 2025; 14(17) doi: 10.3390/jcm14176060
|
| 14 |
Jarosław Jerzy Sak, Andrzej Prystupa, Paweł Kiciński, Dorota Luchowska-Kocot, Ewa Kurys-Denis, Hanna Bis-Wencel. Leukocyte cell-derived chemotaxin-2 and fibroblast growth factor 21 in alcohol-induced liver cirrhosis. World Journal of Hepatology 2021; 13(12): 2071-2080 doi: 10.4254/wjh.v13.i12.2071
|
| 15 |
Manjula Nandakumar, Abu Saleh Md Moin, Manjunath Ramanjaneya, Ahmed Al Qaissi, Thozhukat Sathyapalan, Stephen L. Atkin, Alexandra E. Butler. Severe iatrogenic hypoglycaemia modulates the fibroblast growth factor protein response. Diabetes, Obesity and Metabolism 2022; 24(8) doi: 10.1111/dom.14716
|
| 16 |
Bipneet Singh, Sruthi Ramanan, Waryaam Singh, Gurleen Kaur, Palak Grover, Nidhishri Sridhar. NASH Cirrhosis: A Systematic Review of Phase 2B Trials. Open Journal of Gastroenterology 2025; 15(04) doi: 10.4236/ojgas.2025.154014
|
| 17 |
Khaled A. Nematallah, Amgad Albohy, Noha Swilam. Phytotherapeutic approach to enhance the hepatoprotective activity of some edible plants: Molecular docking and nanoformulation. Journal of Functional Foods 2024; 122 doi: 10.1016/j.jff.2024.106471
|
| 18 |
Sandra Maria Barbalho, Lucas Fornari Laurindo, Vitor Engracia Valenti, Nahum Méndez-Sánchez, Mariana M. Ramírez-Mejía, Ricardo de Alvares Goulart. Organokine-Mediated Crosstalk: A Systems Biology Perspective on the Pathogenesis of MASLD—A Narrative Review. International Journal of Molecular Sciences 2025; 26(23) doi: 10.3390/ijms262311547
|